MCID: CRV033
MIFTS: 46

Cervical Adenosquamous Carcinoma

Categories: Cancer diseases, Reproductive diseases

Aliases & Classifications for Cervical Adenosquamous Carcinoma

MalaCards integrated aliases for Cervical Adenosquamous Carcinoma:

Name: Cervical Adenosquamous Carcinoma 12 15 17 74
Adenosquamous Cell Carcinoma of the Cervix Uteri 12
Adenosquamous Carcinoma of Cervix 12

Classifications:



External Ids:

Disease Ontology 12 DOID:5636
NCIt 51 C4519
UMLS 74 C0346202

Summaries for Cervical Adenosquamous Carcinoma

Disease Ontology : 12 A cervical carcinoma that derives from squamous cells and gland-like cells.

MalaCards based summary : Cervical Adenosquamous Carcinoma, also known as adenosquamous cell carcinoma of the cervix uteri, is related to adenocarcinoma and glassy cell variant cervical adenosquamous carcinoma. An important gene associated with Cervical Adenosquamous Carcinoma is PDGFRA (Platelet Derived Growth Factor Receptor Alpha), and among its related pathways/superpathways are ERK Signaling and Human cytomegalovirus infection. The drugs Cisplatin and Epoetin alfa have been mentioned in the context of this disorder. Affiliated tissues include cervix, lymph node and breast, and related phenotypes are Decreased viability and Decreased viability

Related Diseases for Cervical Adenosquamous Carcinoma

Diseases related to Cervical Adenosquamous Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 115)
# Related Disease Score Top Affiliating Genes
1 adenocarcinoma 29.4 CDKN2A EGFR KDR PTGS2
2 glassy cell variant cervical adenosquamous carcinoma 12.6
3 adenosquamous carcinoma 10.5
4 pulmonary vein stenosis 10.4 KDR PDGFRA
5 hidradenoma 10.3 KRT7 MAML2
6 spinal chordoma 10.3 EGFR KDR PDGFRA
7 benign breast adenomyoepithelioma 10.3 EGFR KRT7
8 oncocytic breast carcinoma 10.3 EGFR KRT7
9 lacrimal gland mucoepidermoid carcinoma 10.3 CRTC1 MAML2
10 solid adenocarcinoma with mucin production 10.3 KRT7 MUC6
11 krukenberg carcinoma 10.2 HNF1B KRT7
12 nephrogenic adenoma of urinary bladder 10.2 KRT7 PAX8
13 nephrogenic adenoma 10.2 KRT7 PAX8
14 duodenum adenocarcinoma 10.2 KRT7 MUC6
15 breast mucoepidermoid carcinoma 10.2 CRTC1 MAML2
16 bile duct cystadenocarcinoma 10.2 KRT7 MUC6
17 bladder benign neoplasm 10.2 KRT7 PAX8
18 appendix disease 10.2 KRT7 MUC6
19 endosalpingiosis 10.2 KRT7 PAX8
20 sensory organ benign neoplasm 10.2 KRT7 PAX8
21 cervix carcinoma 10.2
22 adenomyoma 10.2 KRT7 MUC6
23 cavernous hemangioma 10.2 KDR KRT7 PDGFRA
24 recurrent respiratory papillomatosis 10.2 EGFR PTGS2
25 clear cell adenofibroma 10.2 KRT7 PDGFRA
26 polyposis syndrome, hereditary mixed, 1 10.2 MUC6 PTGS2
27 bronchiolo-alveolar adenocarcinoma 10.2 EGFR KRT7 MUC6
28 horseshoe kidney 10.2 EGFR HNF1B KRT7
29 oral cavity cancer 10.1 CRTC1 EGFR MAML2
30 bursitis 10.1 KDR PTGS2
31 malignant peritoneal mesothelioma 10.1 CDKN2A EGFR
32 anaplastic oligodendroglioma 10.1 CDKN2A EGFR
33 clear cell hidradenoma 10.1 CRTC1 MAML2 PAX8
34 clear cell adenocarcinoma 10.1 HNF1B KRT7 PAX8
35 ovarian cancer 1 10.1 HNF1B KRT7 PAX8
36 malignant ovarian surface epithelial-stromal neoplasm 10.1 HNF1B KRT7 PAX8
37 ovary epithelial cancer 10.1 HNF1B KRT7 PAX8
38 pleomorphic carcinoma 10.0 EGFR KRT7
39 stomach disease 10.0 EGFR MUC6 PTGS2
40 peritoneum cancer 10.0 KRT7 PAX8
41 renal pelvis adenocarcinoma 10.0 HCK KRT7 PAX8
42 renal pelvis carcinoma 10.0 HCK KRT7 PAX8
43 cutaneous mucoepidermoid carcinoma 10.0 CRTC1 KRT7 MAML2
44 warthin tumor 10.0 CRTC1 KRT7 MAML2
45 lipoadenoma 10.0 CRTC1 KRT7 MAML2
46 kidney benign neoplasm 10.0 KRT7 PAX8
47 conn's syndrome 10.0
48 brain cancer 10.0 EGFR KDR NOTCH1 PDGFRA
49 fibrosarcoma of bone 10.0 CDKN2A KDR PDGFRA
50 schneiderian carcinoma 10.0 CRTC1 MAML2 NOTCH1

Graphical network of the top 20 diseases related to Cervical Adenosquamous Carcinoma:



Diseases related to Cervical Adenosquamous Carcinoma

Symptoms & Phenotypes for Cervical Adenosquamous Carcinoma

GenomeRNAi Phenotypes related to Cervical Adenosquamous Carcinoma according to GeneCards Suite gene sharing:

27 (show all 11)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-2 10.54 EGFR
2 Decreased viability GR00173-A 10.54 PDGFRA MAPK8IP1
3 Decreased viability GR00221-A-1 10.54 CDKN2A EGFR HCK KDR PDGFRA
4 Decreased viability GR00221-A-2 10.54 HCK KDR
5 Decreased viability GR00221-A-3 10.54 CDKN2A KDR PDGFRA
6 Decreased viability GR00221-A-4 10.54 CDKN2A EGFR HCK KDR PDGFRA MAPK8IP1
7 Decreased viability GR00301-A 10.54 MAPK8IP1
8 Decreased viability GR00342-S-3 10.54 MAPK8IP1
9 Decreased viability GR00402-S-2 10.54 CDKN2A EGFR HCK KDR PDGFRA MAPK8IP1
10 Reduced mammosphere formation GR00396-S 9.5 EGFR KDR KRT7 MAPK8IP1 NOTCH1 PAX8
11 Synthetic lethal with gemcitabine GR00225-A 8.8 CDKN2A HCK KDR

MGI Mouse Phenotypes related to Cervical Adenosquamous Carcinoma:

47 (show all 15)
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.26 CDKN2A CRTC1 EGFR HCK HNF1B KDR
2 growth/size/body region MP:0005378 10.24 CDKN2A CRTC1 EGFR HCK HNF1B KDR
3 endocrine/exocrine gland MP:0005379 10.21 CDKN2A CRTC1 EGFR HCK HNF1B MAPK8IP1
4 cellular MP:0005384 10.19 CDKN2A EGFR KDR KRT7 MAPK8IP1 NOTCH1
5 cardiovascular system MP:0005385 10.15 CDKN2A EGFR HCK KDR NOTCH1 PAX8
6 embryo MP:0005380 10.13 CDKN2A EGFR HNF1B KDR NOTCH1 PAX8
7 immune system MP:0005387 10.11 CDKN2A CRTC1 EGFR HCK HNF1B KDR
8 mortality/aging MP:0010768 10.1 CDKN2A EGFR HCK HNF1B KDR MAPK8IP1
9 liver/biliary system MP:0005370 9.98 CDKN2A EGFR HNF1B KDR MAPK8IP1 NOTCH1
10 muscle MP:0005369 9.91 CDKN2A EGFR HNF1B KDR NOTCH1 PDGFRA
11 neoplasm MP:0002006 9.8 CDKN2A EGFR HCK NOTCH1 PDGFRA PTGS2
12 no phenotypic analysis MP:0003012 9.73 CDKN2A EGFR KDR PAX8 PDGFRA PTGS2
13 renal/urinary system MP:0005367 9.7 EGFR HNF1B KRT7 NOTCH1 PAX8 PDGFRA
14 respiratory system MP:0005388 9.5 CDKN2A EGFR HCK KDR NOTCH1 PDGFRA
15 skeleton MP:0005390 9.23 CDKN2A EGFR HCK KDR NOTCH1 PAX8

Drugs & Therapeutics for Cervical Adenosquamous Carcinoma

Drugs for Cervical Adenosquamous Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 104)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Cisplatin Approved Phase 4,Phase 3,Phase 2,Phase 1 15663-27-1 2767 441203 84093
2 Epoetin alfa Phase 4,Phase 3 113427-24-0
3 Hematinics Phase 4,Phase 3
4
Paclitaxel Approved, Vet_approved Phase 3,Phase 2,Phase 1 33069-62-4 36314
5
Carboplatin Approved Phase 3,Phase 2,Phase 1 41575-94-4 10339178 38904 498142
6
Topotecan Approved, Investigational Phase 3,Phase 2,Phase 1 119413-54-6, 123948-87-8 60700
7
Bevacizumab Approved, Investigational Phase 3,Phase 2,Phase 1 216974-75-3
8
Vinorelbine Approved, Investigational Phase 3 71486-22-1 44424639 60780
9
Gemcitabine Approved Phase 3,Phase 2,Phase 1 95058-81-4 60750
10
Bleomycin Approved, Investigational Phase 3 11056-06-7 5360373
11
Vindesine Approved, Investigational Phase 3 53643-48-4, 59917-39-4 40839
12
leucovorin Approved Phase 3,Phase 2 58-05-9 143 6006
13
Ifosfamide Approved Phase 3 3778-73-2 3690
14
Vinblastine Approved Phase 3 865-21-4 241903 13342
15
Methotrexate Approved Phase 3 1959-05-2, 59-05-2 126941
16
Fluorouracil Approved Phase 3,Phase 1,Phase 2 51-21-8 3385
17
Folic Acid Approved, Nutraceutical, Vet_approved Phase 3,Phase 2 59-30-3 6037
18
Tirapazamine Investigational Phase 3,Phase 2,Phase 1 27314-97-2
19 Antineoplastic Agents, Phytogenic Phase 3,Phase 2,Phase 1
20 Albumin-Bound Paclitaxel Phase 3,Phase 2,Phase 1
21 Antineoplastic Agents, Immunological Phase 3,Phase 2,Phase 1
22 Antimitotic Agents Phase 3,Phase 2,Phase 1
23 Topoisomerase Inhibitors Phase 3,Phase 2,Phase 1
24 Antibodies, Monoclonal Phase 3,Phase 2,Phase 1
25 Angiogenesis Inhibitors Phase 3,Phase 2,Phase 1
26 Antibodies Phase 3,Phase 2,Phase 1
27 Immunoglobulin G Phase 3,Phase 2,Phase 1
28 Immunologic Factors Phase 3,Phase 2,Phase 1
29 Immunoglobulins Phase 3,Phase 2,Phase 1
30 topoisomerase I inhibitors Phase 3,Phase 2,Phase 1
31 Endothelial Growth Factors Phase 3,Phase 2,Phase 1
32 Mitogens Phase 3,Phase 2,Phase 1
33 Angiogenesis Modulating Agents Phase 3,Phase 2,Phase 1
34 Immunosuppressive Agents Phase 3,Phase 2,Phase 1
35 Anti-Infective Agents Phase 3,Phase 2,Phase 1
36 Antiviral Agents Phase 3,Phase 2,Phase 1
37 Antimetabolites Phase 3,Phase 2,Phase 1
38 Antimetabolites, Antineoplastic Phase 3,Phase 2,Phase 1
39 Nucleic Acid Synthesis Inhibitors Phase 3,Phase 2
40
Isophosphamide mustard Phase 3 0
41 Antirheumatic Agents Phase 3,Phase 1,Phase 2
42 Dermatologic Agents Phase 3
43 Vitamin B Complex Phase 3,Phase 2
44 Anti-Bacterial Agents Phase 3,Phase 2
45 Folic Acid Antagonists Phase 3,Phase 2
46 Alkylating Agents Phase 3,Phase 2
47 Folate Phase 3,Phase 2
48 Vitamin B9 Phase 3,Phase 2
49 Mitomycins Phase 3
50 Antineoplastic Agents, Alkylating Phase 3,Phase 2

Interventional clinical trials:

(show top 50) (show all 73)
# Name Status NCT ID Phase Drugs
1 Epoetin Beta in Treating Anemia in Patients With Cervical Cancer Completed NCT00046969 Phase 4 cisplatin
2 Paclitaxel and Cisplatin or Topotecan With or Without Bevacizumab in Treating Patients With Stage IVB, Recurrent, or Persistent Cervical Cancer Completed NCT00803062 Phase 3 Cisplatin;Paclitaxel;Topotecan Hydrochloride
3 Comparison of Four Combination Chemotherapy Regimens Using Cisplatin in Treating Patients With Stage IVB, Recurrent, or Persistent Cancer of the Cervix Completed NCT00064077 Phase 3 Cisplatin;Gemcitabine Hydrochloride;Paclitaxel;Topotecan Hydrochloride;Vinorelbine Tartrate
4 Radiation Therapy and Cisplatin With or Without Epoetin Alfa in Treating Patients With Cervical Cancer and Anemia Completed NCT00017004 Phase 3 Cisplatin
5 Radiation Therapy With or Without Chemotherapy After Surgery in Treating Patients With Stage IB or Stage IIA Cervical Cancer Completed NCT00003209 Phase 3 cisplatin;fluorouracil;ifosfamide;methotrexate;mitomycin C;vinblastine sulfate;vindesine
6 Comparison of Three Chemotherapy Regimens in Treating Patients With Stage IVB, Recurrent, or Persistent Cervical Cancer Completed NCT00003945 Phase 3 cisplatin;topotecan hydrochloride
7 Radiation Therapy With or Without Cisplatin or Fluorouracil in Treating Patients With Cancer of the Cervix Completed NCT00003078 Phase 3 cisplatin;fluorouracil
8 Radiation Therapy and Cisplatin With or Without Triapine in Treating Patients With Newly Diagnosed Stage IB2, II, or IIIB-IVA Cervical Cancer or Stage II-IVA Vaginal Cancer Recruiting NCT02466971 Phase 3 Cisplatin;Triapine
9 Radiation Therapy With or Without Chemotherapy in Patients With Stage I-IIA Cervical Cancer Who Previously Underwent Surgery Recruiting NCT01101451 Phase 3 Cisplatin
10 Chemotherapy and Pelvic Radiation Therapy With or Without Additional Chemotherapy in Treating Patients With High-Risk Early-Stage Cervical Cancer After Radical Hysterectomy Recruiting NCT00980954 Phase 3 carboplatin;cisplatin;paclitaxel
11 Cisplatin and Radiation Therapy With or Without Carboplatin and Paclitaxel in Patients With Locally Advanced Cervical Cancer Active, not recruiting NCT01414608 Phase 3 Carboplatin;Cisplatin;Paclitaxel
12 Chemotherapy Followed By Surgery Vs Radiotherapy Plus Chemotherapy in Patients With Stage IB or II Cervical Cancer Active, not recruiting NCT00039338 Phase 3 cisplatin
13 Chemotherapy and Radiation Therapy With or Without Surgery in Treating Patients With Stage I Cancer of the Cervix Terminated NCT00054067 Phase 3 cisplatin
14 Cisplatin and Radiation Therapy With or Without Tirapazamine in Treating Patients With Cervical Cancer Terminated NCT00262821 Phase 3 cisplatin;tirapazamine
15 Cisplatin and Radiation Therapy With or Without Hyperthermia Therapy in Treating Patients With Cervical Cancer Terminated NCT00085631 Phase 3 cisplatin
16 Cisplatin Combined With Radiation Therapy and Hyperthermia in Treating Patients With Stage II, Stage III, or Stage IV Cervical Cancer Unknown status NCT00008112 Phase 2 cisplatin
17 Panitumumab, Cisplatin, and Pelvic Radiation Therapy in Treating Patients With Stage IB, Stage II, or Stage III Cervical Cancer Unknown status NCT01158248 Phase 2 cisplatin
18 Paclitaxel and Carboplatin Followed by Cisplatin and Radiation Therapy in Treating Patients With Stage IB, Stage II, Stage III, or Stage IVA Cervical Cancer Unknown status NCT00462397 Phase 2 carboplatin;cisplatin;paclitaxel
19 Bryostatin-1 Plus Cisplatin in Treating Patients With Recurrent or Advanced Cancer of the Cervix Completed NCT00005965 Phase 2 bryostatin 1;cisplatin
20 Capecitabine in Treating Patients With Persistent or Recurrent Cervical Cancer Completed NCT00039442 Phase 2 Capecitabine
21 Ixabepilone to Treat Cervical Cancer Completed NCT00924066 Phase 2 Ixempra (Ixabepilone (BMS-247550) )
22 Brivanib Alaninate in Treating Patients With Persistent or Recurrent Cervical Cancer Completed NCT01267253 Phase 2 Brivanib Alaninate
23 ABI-007 in Treating Patients With Persistent or Recurrent Cervical Cancer Completed NCT00309959 Phase 2 Paclitaxel Albumin-Stabilized Nanoparticle Formulation
24 Pelvic Exenteration in Treating Patients With Recurrent Cervical Cancer Completed NCT00217633 Phase 2
25 Sunitinib Malate in Treating Patients With Uterine Cervical Cancer That is Stage IVB, Recurrent, or Cannot Be Removed By Surgery Completed NCT00389974 Phase 2 sunitinib malate
26 Oxaliplatin and Paclitaxel in Treating Patients With Locally Recurrent or Metastatic Cervical Cancer Completed NCT00057863 Phase 2 Paclitaxel;Oxaliplatin
27 S9717 Tirapazamine Plus Cisplatin in Treating Patients With Metastatic, Recurrent, or Refractory Cervical Cancer Completed NCT00003369 Phase 2 cisplatin;tirapazamine
28 Veliparib, Topotecan Hydrochloride, and Filgrastim or Pegfilgrastim in Treating Patients With Persistent or Recurrent Cervical Cancer Completed NCT01266447 Phase 2 Topotecan Hydrochloride;Veliparib
29 Temsirolimus in Treating Patients With Cervical Cancer That Is Recurrent, Locally Advanced, Metastatic, or Cannot Be Removed By Surgery Completed NCT01026792 Phase 2 Temsirolimus
30 Bevacizumab, Radiation Therapy, and Cisplatin in Treating Patients With Previously Untreated Locally Advanced Cervical Cancer Completed NCT00369122 Phase 2 Cisplatin
31 Irofulven in Treating Patients With Stage IVB or Recurrent Cervical Cancer Completed NCT00005070 Phase 2 irofulven
32 Interleukin-12 in Treating Patients With Advanced or Recurrent Cancer of the Cervix Completed NCT00003017 Phase 2
33 Surgery and Vaccine Therapy in Treating Patients With Early Cervical Cancer Completed NCT00002916 Phase 2
34 Fludeoxyglucose (FDG) F 18 PET Scan, CT Scan, and Ferumoxtran-10 MRI Scan Before Chemotherapy and Radiation Therapy in Finding Lymph Node Metastasis in Patients With Locally Advanced Cervical Cancer or High-Risk Endometrial Cancer Completed NCT00416455 Phase 1, Phase 2 ferumoxtran-10
35 ADXS11-001 High Dose HPV+ Cervical Cancer Completed NCT02164461 Phase 1, Phase 2
36 Carboplatin and Paclitaxel With or Without Cediranib Maleate in Treating Patients With Metastatic or Recurrent Cervical Cancer That Cannot Be Removed by Surgery Completed NCT01229930 Phase 2 carboplatin;cediranib maleate;paclitaxel
37 Carboplatin and Topotecan in Treating Patients With Relapsed or Metastatic Cervical Cancer Completed NCT00807079 Phase 1, Phase 2 carboplatin;topotecan hydrochloride
38 Radiation Therapy and Cisplatin With or Without Amifostine for Patients With Stage IIIB or IVA Cervical Cancer Completed NCT00012012 Phase 1, Phase 2 Amifostine trihydrate;Cisplatin
39 Dose Escalation Study of Simultaneous Boost Intensity-Modulated Radiotherapy for Locally Advanced Cervical Cancer Completed NCT01230996 Phase 1, Phase 2 Cisplatin
40 Radiation Therapy in Treating Patients With Cervical Cancer Completed NCT00278304 Phase 2
41 Cetuximab and Cisplatin in Treating Patients With Advanced, Persistent, or Recurrent Cervical Cancer Completed NCT00101192 Phase 2 cisplatin
42 Cisplatin and Radiation Therapy in Treating Patients With HIV-Associated Locally Advanced Cervical Cancer Completed NCT01590017 Phase 2 cisplatin
43 Paclitaxel, Topotecan, and Cisplatin in Treating Patients With Advanced, Persistent, or Recurrent Cervical Cancer Completed NCT00276796 Phase 2 cisplatin;paclitaxel;topotecan hydrochloride
44 Intensity-Modulated Radiation Therapy to the Pelvis With or Without Chemotherapy in Treating Patients With Endometrial Cancer or Cervical Cancer That Has Been Removed By Surgery Completed NCT00331760 Phase 2 cisplatin
45 Radiation Therapy Plus Celecoxib, Fluorouracil, and Cisplatin in Patients With Locally Advanced Cervical Cancer Completed NCT00023660 Phase 1, Phase 2 celecoxib;cisplatin;fluorouracil
46 Radiation Therapy Plus Paclitaxel and Cisplatin in Treating Patients With Cervical Cancer Completed NCT00003379 Phase 1, Phase 2 cisplatin;paclitaxel
47 Study of Nimotuzumab Combined With Concurrent Chemoradiotherapy for Locally Advanced Cervical Cancer Recruiting NCT03469531 Phase 2 Nimotuzumab;Cisplatin
48 Vaccine Therapy in Treating Patients With Persistent or Recurrent Cervical Cancer Active, not recruiting NCT01266460 Phase 2
49 Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer Active, not recruiting NCT02257528 Phase 2
50 Atezolizumab and Bevacizumab in Treating Patients With Recurrent, Persistent, or Metastatic Cervical Cancer Active, not recruiting NCT02921269 Phase 2 Atezolizumab

Search NIH Clinical Center for Cervical Adenosquamous Carcinoma

Genetic Tests for Cervical Adenosquamous Carcinoma

Anatomical Context for Cervical Adenosquamous Carcinoma

MalaCards organs/tissues related to Cervical Adenosquamous Carcinoma:

42
Cervix, Lymph Node, Breast, Lung, Kidney, Bone, Endothelial

Publications for Cervical Adenosquamous Carcinoma

Articles related to Cervical Adenosquamous Carcinoma:

(show all 11)
# Title Authors Year
1
Cervical adenosquamous carcinoma: detailed analysis of morphology, immunohistochemical profile, and clinical outcomes in 59 cases. ( 30258209 )
2019
2
Leptomeningeal metastasis of poorly differentiated uterine cervical adenosquamous carcinoma following reirradiation to metastatic vertebrae: A case report. ( 28489796 )
2017
3
A case of melanocytic cervical adenosquamous carcinoma complicated with Cushing's syndrome. ( 29767880 )
2017
4
Cervical adenosquamous carcinoma with extension to uterine corpus. ( 27306573 )
2016
5
Duodenal metastasis of cervical adenosquamous carcinoma. ( 22387251 )
2012
6
Outcome analysis of cervical adenosquamous carcinoma compared with adenocarcinoma. ( 22497449 )
2012
7
Cutaneous metastases of cervical adenosquamous carcinoma. ( 20633787 )
2010
8
Molecular characterization of EGFR, PDGFRA and VEGFR2 in cervical adenosquamous carcinoma. ( 19563658 )
2009
9
Prevalence, viral load, and physical status of HPV 16 and 18 in cervical adenosquamous carcinoma. ( 19727809 )
2009
10
Cervical adenosquamous carcinoma: tumor implantation in an episiotomy scar. ( 17666630 )
2007
11
Unusual recurrence of cervical adenosquamous carcinoma after conservative surgery. ( 10684719 )
2000

Variations for Cervical Adenosquamous Carcinoma

Expression for Cervical Adenosquamous Carcinoma

Search GEO for disease gene expression data for Cervical Adenosquamous Carcinoma.

Pathways for Cervical Adenosquamous Carcinoma

Pathways related to Cervical Adenosquamous Carcinoma according to GeneCards Suite gene sharing:

(show all 16)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.62 CDKN2A EGFR HNF1B KDR MAPK8IP1 NOTCH1
2
Show member pathways
12.72 CDKN2A EGFR HCK PDGFRA PTGS2
3
Show member pathways
12.66 EGFR HCK KDR PDGFRA PTGS2
4
Show member pathways
12.63 EGFR KDR MAML2 NOTCH1 PDGFRA PTGS2
5
Show member pathways
12.47 CDKN2A EGFR KDR NOTCH1 PDGFRA
6 12.16 CDKN2A EGFR NOTCH1 PAX8 PDGFRA PTGS2
7 12.03 CDKN2A EGFR NOTCH1 PDGFRA PTGS2
8 11.84 HNF1B KDR NOTCH1
9 11.73 CDKN2A EGFR PDGFRA
10 11.73 EGFR HCK KDR PDGFRA
11 11.36 KDR NOTCH1 PDGFRA
12 11.32 CDKN2A EGFR PDGFRA
13 11.26 KDR MAML2 NOTCH1
14 11.18 EGFR KDR PDGFRA
15 10.94 KDR PDGFRA
16 10.87 KDR NOTCH1 PDGFRA PTGS2

GO Terms for Cervical Adenosquamous Carcinoma

Cellular components related to Cervical Adenosquamous Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 nucleus GO:0005634 9.44 CDKN2A CRTC1 EGFR HCK HNF1B KDR
2 receptor complex GO:0043235 9.26 EGFR KDR NOTCH1 PDGFRA

Biological processes related to Cervical Adenosquamous Carcinoma according to GeneCards Suite gene sharing:

(show all 24)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of transcription, DNA-templated GO:0045893 9.97 CDKN2A EGFR HNF1B NOTCH1 PAX8
2 cell differentiation GO:0030154 9.92 EGFR HCK KDR NOTCH1 PAX8
3 positive regulation of transcription by RNA polymerase II GO:0045944 9.91 CDKN2A CRTC1 EGFR HNF1B MAML2 NOTCH1
4 viral process GO:0016032 9.85 CRTC1 HCK KDR KRT7 PDGFRA
5 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.84 EGFR KDR NOTCH1 PDGFRA
6 positive regulation of cell migration GO:0030335 9.81 EGFR KDR NOTCH1 PDGFRA
7 response to organic cyclic compound GO:0014070 9.79 EGFR HNF1B PTGS2
8 Notch signaling pathway GO:0007219 9.76 HNF1B MAML2 NOTCH1
9 lung development GO:0030324 9.75 EGFR NOTCH1 PDGFRA
10 peptidyl-tyrosine phosphorylation GO:0018108 9.73 EGFR HCK KDR PDGFRA
11 liver development GO:0001889 9.72 EGFR HNF1B NOTCH1
12 protein autophosphorylation GO:0046777 9.71 EGFR HCK KDR PDGFRA
13 positive regulation of cell proliferation GO:0008284 9.63 EGFR HCK KDR NOTCH1 PDGFRA PTGS2
14 positive regulation of MAPK cascade GO:0043410 9.62 KDR PDGFRA
15 regulation of JNK cascade GO:0046328 9.61 EGFR MAPK8IP1
16 embryonic digestive tract morphogenesis GO:0048557 9.6 HNF1B PDGFRA
17 positive regulation of transcription of Notch receptor target GO:0007221 9.59 MAML2 NOTCH1
18 somatic stem cell division GO:0048103 9.56 CDKN2A NOTCH1
19 mesonephric tubule development GO:0072164 9.49 HNF1B PAX8
20 pronephros development GO:0048793 9.48 HNF1B PAX8
21 peptidyl-tyrosine autophosphorylation GO:0038083 9.43 EGFR HCK KDR
22 negative regulation of mesenchymal cell apoptotic process involved in metanephros development GO:1900212 9.32 HNF1B PAX8
23 transmembrane receptor protein tyrosine kinase signaling pathway GO:0007169 9.26 EGFR HCK KDR PDGFRA
24 negative regulation of apoptotic process GO:0043066 9.1 EGFR HCK HNF1B KDR MAPK8IP1 PTGS2

Molecular functions related to Cervical Adenosquamous Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 transmembrane receptor protein tyrosine kinase activity GO:0004714 9.33 EGFR KDR PDGFRA
2 vascular endothelial growth factor-activated receptor activity GO:0005021 9.32 KDR PDGFRA
3 transmembrane signaling receptor activity GO:0004888 9.26 EGFR NOTCH1
4 vascular endothelial growth factor binding GO:0038085 8.96 KDR PDGFRA
5 protein tyrosine kinase activity GO:0004713 8.92 EGFR HCK KDR PDGFRA

Sources for Cervical Adenosquamous Carcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....